The Life Raft Group is partnering with Dr. Candace Haddox of Dana-Farber Cancer Institute to present “Exploring a New Clinical Trial for KIT-Mutant GIST” on December 8th, 2026 at 12:30PM ET. Dr. Haddox will discuss a new clinical trial testing a combination therapy of ripretinib plus navlimetostat for GIST patients with a KIT mutation and MTAP gene deletion. She will review the rationale of the treatment, goals of the trial, participant eligibility, how to enroll, and where to get more information. A Q&A session will follow the presentation.
These webinars are for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider before making any treatment or lifestyle changes.
About Our Presenter:
Dr. Candace Haddox
Dana-Farber Cancer Institute
Dr. Candace Haddox is an Assistant Professor of Medicine at Harvard Medical School, and a medical oncologist and clinical/translational investigator in the Sarcoma Center and the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute. Dr. Haddox’s research focuses on developing novel therapies rooted in sarcoma biology and determining mechanisms of treatment response and resistance, particularly in gastrointestinal stromal tumors (GIST).
Dr. Haddox received her Bachelor of Science in neurobiology from the University of Miami. She completed a post-baccalaureate research fellowship at the National Institutes of Health and received her Medical Degree from the University of South Florida. Dr. Haddox completed a residency in Internal Medicine at the Mayo Clinic in Rochester, Minnesota, and a fellowship in Medical Oncology at Duke University, where she also served as Chief Fellow. She joined the faculty at Dana-Farber Cancer Institute in 2021, where she currently sees patients with sarcomas and leads clinical trials in early drug development.
